Abstract :
Objective: The objective of the present work is to develop a simple, efficient, and reproducible
spectrophotometric method for the quantitative estimation of hepatitis-C drug - Daclatasvir in active
pharmaceutical ingredient (API) form and in pharmaceutical dosage form
Methods: The developed ultraviolet spectrophotometric method for the quantitative estimation of hepatitis-C drugs -
Daclatasvir based on measurement of absorption at a wavelength maximum (λmax) of 317 nm using
methanol as solvent.
Results: The method was validated in terms of, precision, linearity, accuracy, and robustness, LOD, LOQ as per the
ICH guidelines. The method was found to be linear in the range of 50-150% for Daclatasvir. The percentage
recovery values were in the range of 99.9-100.9% for Daclatasvir at different concentration levels. Relative
standard deviation for precision and intermediate precision results were found to be
Keyword :
Daclatasvir, Method development, Validation, Ultraviolet-visible spectrophotometry.